100 Years In India – GSK’s Secret Sauce To Not Just Stay Relevant But Thrive

GlaxoSmithKline Pharmaceuticals’ MD tells Scrip how the company has been able to reinvent itself, contemporize brands and get supply chain innovation right as the UK-headquartered firm marks 100 years of operations in India. GSK’s equivalent of the 'Amazon model' for vaccine ordering and the new temples of industry are some of the other facets the executive discussed in the first instalment of this two-part interview.

Bhushan Akshikar, managing director, GlaxoSmithKline Pharmaceuticals Ltd • Source: GSK

From the days of infant formula milk in the 1920s to new age vaccines and therapies now, GSK’s 100-year journey in India in many ways mirrors the story of the country’s evolving healthcare needs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Boehringer Ingelheim, Tessellate Bio Link For Precision Therapies For ALT Tumors

24 Apr 2025

• By Sushmita Panda

In its first pharma collaboration, Tessellate Bio has inked a deal potentially worth more than €500m with Boehringer Ingelheim for therapies for ALT tumors.

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

24 Apr 2025

• By Lisa Takagi

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.

Genentech To Try Repertoire’s Immune Synapse Technology In Autoimmune Disease

23 Apr 2025

• By Joseph Haas

Deal snapshot: The Flagship portfolio firm will use its Decode platform to seek novel targets for an unspecified autoimmune disease, with Genentech holding license rights.

Veraxa Takes SPAC Route To Develop Bispecific ADCs and T-Cell Engagers

23 Apr 2025

• By Andrew McConaghie

The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.

Samsung Bioepis Reevaluating Approach To Biosimilars

04 Apr 2025

• By Jessica Merrill

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.